Connecting the Human Variome Project to nutrigenomics
- 152 Downloads
Nutrigenomics is the science of analyzing and understanding gene–nutrient interactions, which because of the genetic heterogeneity, varying degrees of interaction among gene products, and the environmental diversity is a complex science. Although much knowledge of human diversity has been accumulated, estimates suggest that ~90% of genetic variation has not yet been characterized. Identification of the DNA sequence variants that contribute to nutrition-related disease risk is essential for developing a better understanding of the complex causes of disease in humans, including nutrition-related disease. The Human Variome Project (HVP; http://www.humanvariomeproject.org/) is an international effort to systematically identify genes, their mutations, and their variants associated with phenotypic variability and indications of human disease or phenotype. Since nutrigenomic research uses genetic information in the design and analysis of experiments, the HVP is an essential collaborator for ongoing studies of gene–nutrient interactions. With the advent of next generation sequencing methodologies and the understanding of the undiscovered variation in human genomes, the nutrigenomic community will be generating novel sequence data and results. The guidelines and practices of the HVP can guide and harmonize these efforts.
KeywordsNutrigenomics Human Variome Project Harmonization
Nutrigenomics has been called a “post-genome” field of research (e.g., ) because it could only develop in a meaningful way after the completion of the sequencing of the human genome. Ideally, nutrigenomics experiments are to be designed, conducted, and analyzed with specific knowledge of genes involved in nutrient metabolism and physiological processes. Data from the Human Genome project and subsequent haplotype mapping projects [14, 59, 60, 61, 70] demonstrated that any two humans will differ by 3–5 million bases. However, ongoing re-sequencing of individual genomes has now identified ~18 million single nucleotide polymorphisms [4, 29, 47]. More recent studies have also shown structural variation in the human genome indicating that approximately 13% of the variation between humans may be due to copy number [1, 31, 41, 50, 68, 71]. The ongoing discovery of new SNPs and structural variants shows that the genomic era is far from ending, particularly since the next generation sequencing technologies  will soon allow for complete analyses of all coding sequences (i.e., the exome) of all individuals in a research study (e.g., ) or even for the complete sequencing of individual genes, including the regulatory regions.
1,000 Genomes populationsa
Han Chinese in Beijing, China
Southern Han Chinese
Han Chinese south
Chinese Dai in Xishuangbanna, China
Chinese in Denver, Colorado (pilot 3 only)
Japanese in Tokyo, Japan
Kinh in Ho Chi Minh City, Vietnam
Utah residents (CEPH) with Northern and Western European ancestry
Toscani in Italia
British in England and Scotland
Finnish in Finland
Iberian populations in Spain
Yoruba in Ibadan, Nigeria
Luhya in Webuye, Kenya
Gambian in Western Division, The Gambia
Ghanaian in Navrongo, Ghana
Malawian in Blantyre, Malawi
African Ancestry in Southwest US
African American in Jackson, Mississippi
African Caribbean in Barbados
Mexican Ancestry in Los Angeles, California
Colombian in Medellin, Colombia
Peruvian in Lima, Peru
Puerto Rican in Puerto Rico
The Human Variome Project
The Human Variome Project (HVP; http://www.humanvariomeproject.org/) is an international effort to systematically identify genes, their mutations, and their variants associated with phenotypic variability and indications of human disease or phenotype [15, 16, 33, 51]. The goal of the HVP is to link clinical, medical, and research laboratories for developing knowledge. This knowledge will be accessible to the research and medical communities to improve research strategies and clinical medical practice. One of the key deliverables of the HVP is the creation of a cyber infrastructure to link locus-specific databases (LSDBs ). These databases have similar architecture, ontologies, and data elements allowing for interoperability and are curated by local experts. Over 700 LSDBs are maintained across the world and accessible at the Human Genome Variation Society website (http://www.hgvs.org/dblist/glsdb.html). Some, but not all, of the information in LSDBs are consolidated in national and international databases such as at the National Center for Biotechnology Information (NCBI—http://www.ncbi.nlm.nih.gov/) and the European Bioinformatics Institute (EBI—http://www.ebi.ac.uk/).
Capture and archive all human gene variation associated with human disease in a central location with mirror sites in other countries. Data governance will ensure security and integrity through the use of auditing and security technologies but nevertheless allow searching across all genes using a common interface.
Provide a standardized system of gene variation nomenclature, reference sequences, and support systems that will enable diagnostic laboratories to use and contribute to total human variation knowledge.
Establish systems that ensure adequate curation of human variation knowledge from gene-specific (locus-specific), country-specific, or disease-specific database perspective to improve accuracy, reduce errors, and develop a comprehensive data set comprising all human genes.
Facilitate the development of software to collect and exchange human variation data in a federation of gene-specific (locus-specific), country-specific, disease-specific, and general databases.
Establish a structured and tiered mechanism that clinicians can use to determine the health outcomes associated with genetic variation. This will work as a dialog between those who use human variation data and those who provide them. Clinicians will be encouraged to provide data and will have open access to complete variation data.
Create a support system for research laboratories that provides for the collection of genotypic and phenotypic data together using the defined reference sequence in a free, unrestricted, and open access system and create a simple mechanism for logging discoveries.
Develop ethical standards to ensure open access to all human variation data that are to be used for global public good and address the needs of “indigenous” communities under the threat of dilution in emerging countries.
Provide support to developing countries to build capacity and to fully participate in the collection, analysis, and sharing of genetic variation information.
Establish a communication and education program to collect and spread knowledge related to human variation knowledge to all countries of the world.
Continue to carry out research within the opportunities presented by the investigation of human genetic variation and to present these findings to users of this information for the benefit of all.
The Nutrigenomics Organization (NuGO)
NuGO was established as an association of 23 universities and research institutes focusing on jointly developing the exiting research area of nutrigenomics and nutritional systems biology. NuGO evolved from an EU Sixth Framework Network of Excellence and has now transitioned into a global association encompassing individuals and institutions around the globe.
stimulating developments in nutrigenomics, nutrigenetics, and nutritional systems biology and incorporating these aspects in nutrition and health research, by joint research projects, conferences, workshops, and training. As a legal, nonprofit entity, NuGO can join as partner in research projects anywhere in the world.
shaping the nutrition bioinformatics infrastructure, by initiating, coordinating, facilitating projects in this area and by hosting and disseminating all data, results and information in this area.
The common goals of nutrigenomic community and the Human Variome Project
The HVP established committees to develop action plans to meet the 10 key objectives, which overlap or parallel the goals described in a consensus statement authored by 89 international scientists in the nutrigenomics community , which was co-authored by the members of NuGO. The parallel objectives of the HVP and NuGO are the common grounds upon which the two scientific communities base their interaction, as schematically described in Fig. 1.
The HVP captures and classifies genetic variation from voluntary contributions from unlinked clinical, research, diagnostic, and service laboratories. The nutrigenomic community had not specifically designated the identification and characterization of variation as a goal, even though many researchers interested in nutrient–phenotype associations use that knowledge in their experiments (e.g., [45, 56]). The emerging consensus that rare polymorphisms (i.e., <1% in the population) and copy number variants  may influence health, disease, and nutrient–gene interactions makes it imperative that nutrigenomic researchers adopt and use sequence technologies and methods as a part of their experimental design and procedures.
Assessment of pathogenicity—the phenotype
Deleterious gene–phenotype associations are described as pathogenicity in clinical settings and are described by genetic, clinical phenotype, and pathology. Basic researchers use the term deep phenotyping  when analyzing large numbers of genes, metabolites, proteins, or transcripts, or combinations of omic technologies. These methodologies are being adopted to the clinic for assessments (e.g., [24, 57]) and have led to the application of interdisciplinary, primary care, community-based, and translational research [25, 40, 69] to health and disease studies, blurring the distinction between basic and clinical research .
Data transfer, integration, and access are among the major challenges facing the biomedical researcher in the 21st century. The abstracts for over 19 million are available in PubMed in the U.S. National Library of Medicine’s database of publications. Inclusion of quantitative measures of genetic and environmental variations would likely influence the results of many of these studies. However, only a small fraction of full texts and additional data for these publications is electronically accessible. Moreover, much of these data are discipline specific, making it a challenge to mine public-domain results for linked data or knowledge. The HVP is developing standards with international databases (NCBI and EBI) and projects (e.g., European Union Gen2Phen initiative—http://www.gen2phen.org). The nutrigenomic community faces a greater challenge since few tools or databases are available for nutrition-related research . Two related initiatives are underway to address these limitations. The Nutrigenomics Organization has begun the development of a nutritional phenotype database (dbNP—), a research and collaboration tool, and knowledge base which will allow access to publically available data. A separate yet key component of dbNP is WikiPathways [36, 48], an open, collaborative platform for the curation of biological pathways (http://www.wikipathways.org) based on all data available to the curator.
About 90% of known SNPs are shared between Asians, Europeans, and Africans and the remaining polymorphisms, called private SNPs, are distributed among these populations [26, 30]. The recent sequencing of the genomes of several individuals (e.g., [5, 38, 66, 67]), along with gene-specific re-sequencing efforts suggest that a larger number of SNPs than previously determined, as well as other sequence variation, exist in the human population. Estimates from African genetic diversity and the Pan Asian SNP initiative indicate that 80 to 90% of human genomic variation resides in the world’s emerging countries. The Population Reference Sample (POPRES ) targets populations not previously included in the HapMap project, similar to the 1,000 Genomes initiative. The main focus of the HVP effort is the inclusion and analyses of clinical samples from diverse ethnic groups. One of the advantages of including some ethnic populations is the opportunity to study genetic diseases due to consanguinity, large family size, and potential founder effects (e.g., [10, 11, 52]). Although nutrigenomic researchers do not necessarily include such populations, unique genetic groups may yield valuable insights into understanding the distribution of gene–nutrient interactions in health and disease processes .
Biomedical research has not typically been the focus of resource for poor countries, even though such activities are likely to produce economic and health benefits for all [20, 54]. The recently announced global alliance for chronic disease (GACD—) addresses the increasing consensus that emerging economies face not only malnutrition but also the development of chronic diseases, a double economic and health burden. Education of health care providers, the public, and government officials is needed for demonstrating the universal nature of the HVP’s and NuGO’s research efforts, the need to include populations in developing countries, and the benefits from cooperating in biomedical research ([8, 13, 53, 62].
The NIH National Center for Minority Health and Health Disparities (NCMHD) recently called for a paradigm shift to include minority, low socioeconomic and rural populations, and individuals in biomedical research [21, 22]. From the perspective of the science underlying both the HVP and nutrigenomic research efforts, understanding the full spectrum of genetic or metabolic spectra will not be possible without the involvement of all ancestral groups. Including these populations and individuals may allow for a more rapid translation of basic science to society. Community-based participatory research collaborations may provide forums for addressing cultural and ethical concerns of biomedical research . The genomic sovereignty/equality for all countries to be involved in their research efforts is an accepted norm of the HVP and nutrigenomic research communities. The value of ‘human capital’ within all populations is acknowledged and treasured. Real and tangible benefits of biomedical research to improve health will be generated for participating populations; the voluntary participation of the greatest number of countries would ensure targeted interventions to improve personal and public health.
HVP and nutrigenomic researchers are committed to adhering to the highest ethical principles governing research, data sharing, and ultimately enabling this new knowledge to benefit all of the humanity. Ethical guidelines specifically for LSDBs were previously published , and new guidelines are in process . NuGO has also published bioethical guidelines [6, 7]. The ethics of international health research continue to evolve with a greater emphasis on development and social justice , values which are consistent with the stated goals of the HVP and nutrigenomics researchers [34, 51].
A key ethical concern for the Human Variome Project and eventually for data generated from individuals in nutrigenomics research is the accessibility of research data on public websites. For HVP, rare mutations in a population open the possibility of identifying the research participant. For both fields of research, polygenic analyses (e.g., whole genome scans) have yielded the identification of single participants in research studies. Such polygenic analyses generate data that could be used for re-identifying individual patients  but is less likely in single gene diseases.
The HVP is developing an ethics review committee with a subcommittee focused on issues related to LSDB for (i) providing counsel when dilemmas arise, (ii) overseeing guidelines, (iii) identifying best practices, (iv) determining how best to ensure privacy in all situations, (v) formulating how to handle data for which explicit consent does not exist or is not possible to achieve, and (vi) developing a consent form that is consistent for all LSDBs but which can be adapted to the requirements of individual countries. NuGO has an ethics committee, and several members are also members of the HVP ethics group.
Funding and governance
International collaborations of the scope of the HVP and nutrigenomics efforts are rarely funded. Rather, both organizations believe that distributed financing for distributed science is more likely to occur. To make a distributive model feasible, best practices and harmonized protocols are necessary. The HVP is developing the standards for LSDB’s and reporting, and NuGO has a rich tradition of developing standard operating procedures for methodologies (http://www.nugo.org/sops). Several international efforts are currently being designed for type 2 diabetes and micronutrient genomics . Guidelines and policies of the HVP will be adopted for both of these protocols since both require analyses of phenotype based on genetic differences in study participants. The HVP is managed by the Genomic Disorders Research Center (Melbourne, Australia; http://www.genomic.unimelb.edu.au), and NuGO has a coordinating council consisting of European scientists from member Institutions.
Attribution and publication
Large scale science requires novel approaches for attributing contributions. High throughput technologies generate a large number of raw data whose availability represents a great advantage to all scientists working in the field. These data sets are often unpublished and made available to all through deposition in public databases. This creates the need to define new criteria for the attribution of unpublished data and requires a policy of credits and incentives to be coordinated between database curators and the editors of scientific journals. For the nutrigenomics projects, harmonized, distributive funding allows for the publication of local studies, and the possibility of comprehensive analyses of all data by a team consisting of individuals from multiple disciplines and regions. The HapMap project and other international projects have previously developed procedures for publication credit. The HVP faces additional challenges since clinics and service laboratories describe pathogenicity and genetic variation, but academic incentives to publish are not paramount for these professions. Novel approaches for attribution have been proposed [23, 33, 43] and are starting to be applied by some databases and continue to be developed by the HVP. A public debate is also in progress among the editors of genetics journals to coordinate efforts toward the attribution of data deposition and database linking (http://www.gen2phen.org/wiki/hvp-publication-credit-and-incentives-recommendations).
Connecting the projects
Members of the HVP and nutrigenomics community have attended conferences and workshops, including the 3rd Asia Pacific Nutrigenomics conference (Melbourne, 2008), the Fifth China Health Annual for the announcement of the HVP node in Beijing (2008), the Symposium of Princess Al-Jawhara Center of Excellence in Research of Hereditary Disorders (King Abdulaziz University. Jeddah, Saudi Arabia), the Third HVP planning meeting (Costa Brava, Spain) and at the Fourth HVP meeting (Roadmap: Project structure) at UNESCO (Paris, France). NuGO organized a micronutrient genomics workshop at the UNESCO meeting. Future meetings include co-hosting workshops at the International Conference on Nutrigenomics (ICON) in Guaruja’, Brazil (September 2010). The HVP and NuGO are exploring the best means to formally recognize their ongoing interactions. The HVP has a similar ongoing relationship with the International Society for Gatrointestinal Hereditary Tumors (http://www.insight-group.org).
Organisms are complex systems that are regulated by interactions between multiple environmental factors and multiple genes. Analyzing complex systems requires a multidisciplinary and multi-technological approach (i.e., omics). Since each person or team has a limited level of complexity, the ideal, and indeed, the only, approach to understand biological systems is to distribute the task among many teams (see ). The interaction between the HVP and nutrigenomics researchers leverages the expertise of both groups and fosters a more complete analysis of the human organism. These articles will assist the process of populating the human genome sequence with variations which are biologically and medically relevant and eventually provide the complete “human variome.”
- 2.Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Bonnen PE, de Bakker PI, Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker P, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler D, Muzny DM, Barnes C, Darvishi K, Hurles M, Korn JM, Kristiansson K, Lee C, McCarrol SA, Nemesh J, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N, Gonzaga-Jauregui C, Anttila V, Brodeur W, Daly MJ, Leslie S, McVean G, Moutsianas L, Nguyen H, Zhang Q, Ghori MJ, McGinnis R, McLaren W, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, Sabeti PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca MC, Marshall PA, Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, Royal CD, Sharp RR, Zeng C, Brooks LD, McEwen JE (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52–58CrossRefPubMedGoogle Scholar
- 3.Bar-Yam Y (2004) Making things work: solving complex problems in a complex world. NECSI- Knolwedge Press, Cambridge, p 306Google Scholar
- 5.Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, Hall KP, Evers DJ, Barnes CL, Bignell HR, Boutell JM, Bryant J, Carter RJ, Keira Cheetham R, Cox AJ, Ellis DJ, Flatbush MR, Gormley NA, Humphray SJ, Irving LJ, Karbelashvili MS, Kirk SM, Li H, Liu X, Maisinger KS, Murray LJ, Obradovic B, Ost T, Parkinson ML, Pratt MR, Rasolonjatovo IM, Reed MT, Rigatti R, Rodighiero C, Ross MT, Sabot A, Sankar SV, Scally A, Schroth GP, Smith ME, Smith VP, Spiridou A, Torrance PE, Tzonev SS, Vermaas EH, Walter K, Wu X, Zhang L, Alam MD, Anastasi C, Aniebo IC, Bailey DM, Bancarz IR, Banerjee S, Barbour SG, Baybayan PA, Benoit VA, Benson KF, Bevis C, Black PJ, Boodhun A, Brennan JS, Bridgham JA, Brown RC, Brown AA, Buermann DH, Bundu AA, Burrows JC, Carter NP, Castillo N, Chiara ECM, Chang S, Neil Cooley R, Crake NR, Dada OO, Diakoumakos KD, Dominguez-Fernandez B, Earnshaw DJ, Egbujor UC, Elmore DW, Etchin SS, Ewan MR, Fedurco M, Fraser LJ, Fuentes Fajardo KV, Scott Furey W, George D, Gietzen KJ, Goddard CP, Golda GS, Granieri PA, Green DE, Gustafson DL, Hansen NF, Harnish K, Haudenschild CD, Heyer NI, Hims MM, Ho JT, Horgan AM, Hoschler K, Hurwitz S, Ivanov DV, Johnson MQ, James T, Huw Jones TA, Kang GD, Kerelska TH, Kersey AD, Khrebtukova I, Kindwall AP, Kingsbury Z, Kokko-Gonzales PI, Kumar A, Laurent MA, Lawley CT, Lee SE, Lee X, Liao AK, Loch JA, Lok M, Luo S, Mammen RM, Martin JW, McCauley PG, McNitt P, Mehta P, Moon KW, Mullens JW, Newington T, Ning Z, Ling Ng B, Novo SM, O’Neill MJ, Osborne MA, Osnowski A, Ostadan O, Paraschos LL, Pickering L, Pike AC, Chris Pinkard D, Pliskin DP, Podhasky J, Quijano VJ, Raczy C, Rae VH, Rawlings SR, Chiva Rodriguez A, Roe PM, Rogers J, Rogert Bacigalupo MC, Romanov N, Romieu A, Roth RK, Rourke NJ, Ruediger ST, Rusman E, Sanches-Kuiper RM, Schenker MR, Seoane JM, Shaw RJ, Shiver MK, Short SW, Sizto NL, Sluis JP, Smith MA, Ernest Sohna Sohna J, Spence EJ, Stevens K, Sutton N, Szajkowski L, Tregidgo CL, Turcatti G, Vandevondele S, Verhovsky Y, Virk SM, Wakelin S, Walcott GC, Wang J, Worsley GJ, Yan J, Yau L, Zuerlein M, Mullikin JC, Hurles ME, McCooke NJ, West JS, Oaks FL, Lundberg PL, Klenerman D, Durbin R, Smith AJ (2008) Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456(7218):53–59CrossRefPubMedGoogle Scholar
- 9.Biesecker LG, Mullikin JC, Facio FM, Turner C, Cherukuri PF, Blakesley RW, Bouffard GG, Chines PS, Cruz P, Hansen NF, Teer JK, Maskeri B, Young AC, Manolio TA, Wilson AF, Finkel T, Hwang P, Arai A, Remaley AT, Sachdev V, Shamburek R, Cannon RO, Green ED (2009) The clinseq project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res 19(9):1665–1674CrossRefPubMedGoogle Scholar
- 23.Editorial (2008) Human variome microattribution reviews. Nat Genet 40 (1)Google Scholar
- 33.Kaput J, Cotton RG, Hardman L, Watson M, Al Aqeel AI, Al-Aama JY, Al-Mulla F, Alonso S, Aretz S, Auerbach AD, Bapat B, Bernstein IT, Bhak J, Bleoo SL, Blocker H, Brenner SE, Burn J, Bustamante M, Calzone R, Cambon-Thomsen A, Cargill M, Carrera P, Cavedon L, Cho YS, Chung YJ, Claustres M, Cutting G, Dalgleish R, den Dunnen JT, Diaz C, Dobrowolski S, Dos Santos MR, Ekong R, Flanagan SB, Flicek P, Furukawa Y, Genuardi M, Ghang H, Golubenko MV, Greenblatt MS, Hamosh A, Hancock JM, Hardison R, Harrison TM, Hoffmann R, Horaitis R, Howard HJ, Barash CI, Izagirre N, Jung J, Kojima T, Laradi S, Lee YS, Lee JY, Gil-da-Silva-Lopes VL, Macrae FA, Maglott D, Marafie MJ, Marsh SG, Matsubara Y, Messiaen LM, Moslein G, Netea MG, Norton ML, Oefner PJ, Oetting WS, O’Leary JC, de Ramirez AM, Paalman MH, Parboosingh J, Patrinos GP, Perozzi G, Phillips IR, Povey S, Prasad S, Qi M, Quin DJ, Ramesar RS, Richards CS, Savige J, Scheible DG, Scott RJ, Seminara D, Shephard EA, Sijmons RH, Smith TD, Sobrido MJ, Tanaka T, Tavtigian SV, Taylor GR, Teague J, Topel T, Ullman-Cullere M, Utsunomiya J, van Kranen HJ, Vihinen M, Webb E, Weber TK, Yeager M, Yeom YI, Yim SH, Yoo HS (2009) Planning the Human Variome Project: the Spain report. Hum Mutat 30(4):496–510CrossRefPubMedGoogle Scholar
- 34.Kaput J, Ordovas JM, Ferguson L, van Ommen B, Rodriguez RL, Allen L, Ames BN, Dawson K, German B, Krauss R, Malyj W, Archer MC, Barnes S, Bartholomew A, Birk R, van Bladeren P, Bradford KJ, Brown KH, Caetano R, Castle D, Chadwick R, Clarke S, Clement K, Cooney CA, Corella D, Manica da Cruz IB, Daniel H, Duster T, Ebbesson SO, Elliott R, Fairweather-Tait S, Felton J, Fenech M, Finley JW, Fogg-Johnson N, Gill-Garrison R, Gibney MJ, Gillies PJ, Gustafsson JA, Hartman Iv JL, He L, Hwang JK, Jais JP, Jang Y, Joost H, Junien C, Kanter M, Kibbe WA, Koletzko B, Korf BR, Kornman K, Krempin DW, Langin D, Lauren DR, Ho Lee J, Leveille GA, Lin SJ, Mathers J, Mayne M, McNabb W, Milner JA, Morgan P, Muller M, Nikolsky Y, van der Ouderaa F, Park T, Pensel N, Perez-Jimenez F, Poutanen K, Roberts M, Saris WH, Schuster G, Shelling AN, Simopoulos AP, Southon S, Tai ES, Towne B, Trayhurn P, Uauy R, Visek WJ, Warden C, Weiss R, Wiencke J, Winkler J, Wolff GL, Zhao-Wilson X, Zucker JD (2005) The case for strategic international alliances to harness nutritional genomics for public and personal health. Br J Nutr 94(5):623–632CrossRefPubMedGoogle Scholar
- 38.Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC (2007) The diploid genome sequence of an individual human. PLoS Biol 5(10):e254CrossRefPubMedGoogle Scholar
- 44.Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, Briley LP, Maruyama Y, Waterworth DM, Waeber G, Vollenweider P, Oksenberg JR, Hauser SL, Stirnadel HA, Kooner JS, Chambers JC, Jones B, Mooser V, Bustamante CD, Roses AD, Burns DK, Ehm MG, Lai EH (2008) The population reference sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet 83(3):347–358CrossRefPubMedGoogle Scholar
- 49.Povey S, Al Aqeel AI, Cambon-Thomsen A, Dalgleish R, den Dunnen JT, Firth HV, Greenblatt MS, Barash CI, Parker M, Patrinos GP, Savige J, Sobrido MJ, Winship I, Cotton RG (2010) Practical guidelines addressing ethical issues pertaining to the curation of human locus-specific variation databases (LSDBs). Hum Mutat [Epub ahead of print]Google Scholar
- 50.Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME (2006) Global variation in copy number in the human genome. Nature 444(7118):444–454CrossRefPubMedGoogle Scholar
- 58.Stumbo P, Weiss R, Newman J, Pennington J, Tucker K, Wiesenfeld P, Illner A-K, Klurfeld D, Kaput J (2010) Omics and environmental assessments: survey, needs, and plans of the US nutrition and nutrigenomic communities. J Nutr (in press)Google Scholar
- 61.The International HapMap C. (2005) A haplotype map of the human genome. Nature 437(7063): 1299-1320Google Scholar
- 64.van Ommen B, Bouwman J, Dragsted L, Drevon C, Elliott R, de Groot P, Kaput J, Mathers J, Muller M, Pepping F, Saito J, Scalbert A, Radonjic M, Rocca-Serra P, Travis T, Wopereis S, Evelo C (2010) Challenges of molecular nutrition research 6: the nutritional phenotype database to store, share and evaluate nutritional systems biology studies. Genes Nutr (in press)Google Scholar
- 65.van Ommen B, El-Sohemy A, Hesketh J, Kaput J, Fenech M, Evelo C, McArdle H, Bouwman J, Lietz G, Mathers J, Fairweather-Tait S, van Kranen H, van Kranen H, Elliott R, Wopereis S, Ferguson L, Méplan M, Perozzi G, Allen L, Rivero D, Group aTMGPW (2010) The micronutrient genomics project: creating a community driven knowledge base for micronutrient research. Genes Nutr (in press)Google Scholar
- 66.Wang J, Wang W, Li R, Li Y, Tian G, Goodman L, Fan W, Zhang J, Li J, Guo Y, Feng B, Li H, Lu Y, Fang X, Liang H, Du Z, Li D, Zhao Y, Hu Y, Yang Z, Zheng H, Hellmann I, Inouye M, Pool J, Yi X, Zhao J, Duan J, Zhou Y, Qin J, Ma L, Li G, Zhang G, Yang B, Yu C, Liang F, Li W, Li S, Ni P, Ruan J, Li Q, Zhu H, Liu D, Lu Z, Li N, Guo G, Ye J, Fang L, Hao Q, Chen Q, Liang Y, Su Y, San A, Ping C, Yang S, Chen F, Li L, Zhou K, Ren Y, Yang L, Gao Y, Yang G, Li Z, Feng X, Kristiansen K, Wong GK, Nielsen R, Durbin R, Bolund L, Zhang X, Yang H (2008) The diploid genome sequence of an Asian individual. Nature 456(7218):60–65CrossRefPubMedGoogle Scholar
- 67.Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM (2008) The complete genome of an individual by massively parallel DNA sequencing. Nature 452(7189):872–876CrossRefPubMedGoogle Scholar
- 71.Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, Robidoux F, Laflamme P, Cotterchio M, Greenwood C, Scherer SW, Zanke B, Hudson TJ, Bader GD, Gallinger S (2007) Germ-line DNA copy number variation frequencies in a large North American population. Hum Genet 122(3–4):345–353CrossRefPubMedGoogle Scholar